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Abstract: Solid lipid nanoparticles (SLNs) of coenzyme Q10 (CoQ10) were formulated by a 
high-pressure homogenization method. The best formulation of SLN dispersion consisted of 
13% lipid (cetyl palmitate or stearic acid), 8% surfactant (Tween 80 or Tego Care 450), and 
water. Stability tests, particle size analysis, differential scanning calorimetry, transmission 
electron microscopy, and release study were conducted to find the best formulation. A simple 
cream of CoQ10 and a cream containing CoQ10-loaded SLNs were prepared and compared 
on volunteers aged 20–30 years. SLNs with particle size between 50 nm and100 nm exhibited 
the most suitable stability. In vitro release profiles of CoQ10 from simple cream, SLN alone, 
and CoQ10-loaded SLN cream showed prolonged release for SLNs compared with the simple 
cream, whereas there was no significant difference between SLN alone and SLN in cream. 
In vitro release studies also demonstrated that CoQ10-loaded SLN and SLN cream possessed a 
biphasic release pattern in comparison with simple cream. In vivo skin hydration and elasticity 
studies on 25 volunteers suggested good dermal penetration and useful activity of Q10 on skin 
as a hydratant and antiwrinkle cream.
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Introduction
Coenzyme Q10 (CoQ10) is a naturally occurring, lipid-soluble, and chemically 
unstable compound that is synthesized by mammals and plants and serves as a potent 
antioxidant. CoQ10 has been reported to have beneficial effects on the heart, lungs, 
liver, and skin.1,2 It has been shown that by lowering matrix metalloproteinase levels 
in fibroblasts, CoQ10 reduces wrinkles.3 CoQ10 also exerts anti-inflammatory effects 
on dermal fibroblasts.4 In a clinical study, application of 1% Q10 cream for 5 months 
effectively reduced wrinkle score grade.3 The level of Q10 in skin declines with age 
and ultraviolet (UV) irradiation. In skin, the epidermis contains 10-fold higher Q10 
than does the dermis.5 The epidermis as the most outer layer of the skin is directly 
exposed to UV irradiation and other environmental factors, which makes it susceptible 
to depletion of skin antioxidants such as Q10;6 therefore, the epidermis may represent 
a tissue that presumably benefits most from topically applied Q10.3 CoQ10 can retard 
loss of hyaluronic acid and slowdown of cell division, both of which are manifestations 
of intrinsic aging. According to the in vitro data, aged human fibroblasts produce less 
glycosaminoglycan and proliferate more slowly than do young cells. The addition of 
Q10 increases levels of glycosaminoglycan as well as rates of cell division.7
Solid lipid nanoparticles (SLNs) have been introduced as a potent carrier system 
for various pharmaceutical and cosmetic active compounds. They are capable of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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protecting unstable active compounds against degradation,8 
releasing the active ingredients in a controlled way9 and pro-
longing residence time of some actives such as sunscreens 
in the stratum corneum,10 as well as targeting drug to the 
upper layer of skin.11 They also show occlusive properties 
in vitro and decrease water evaporation from the skin to the 
atmosphere.12,13 Occlusion promotes the penetration of actives 
into the skin. Due to the reduced water loss caused by occlu-
sion, skin hydration is increased after dermal application of 
SLN or SLN-containing formulations. In a comparative study, 
the SLN-containing oil-in-water (o/w) cream increased the 
skin hydration significantly more than did conventional o/w 
cream.14 Increased penetration of CoQ10 was described after 
application of Q10-loaded SLN suspension in comparison 
with solutions of isopropanol and liquid paraffin.15,16
SLNs represent a highly effective carrier for cosmetic 
creams that are intended to increase skin hydration. It was 
shown that incorporation of CoQ10 into an SLN matrix 
also provides good chemical stability, so we decided to add 
CoQ10 to SLNs. In order to evaluate the release pattern, 
SLN dispersions were further processed to o/w creams to 
mimic professional use in cosmetics and were evaluated 
both in vitro and in vivo. The aim of the in vivo study was 
the investigation of the effect of loading Q10 in the form of 
SLNs compared with the simple form by measuring hydra-
tion and elasticity of skin.
Material and methods
Materials
Compritol 888ATO (glyceryl behenate), Precifac ATO (cetyl 
palmitate), and Labrasol (PEG-8 caprylic/capric triglycerols) 
were purchased from Gattefosse (Cedex, France). Tego Care 
450 (polyglyceryl-3 methylglucose distearate) was obtained 
from Goldschmidt (Essen, Germany). Stearyl alcohol, cetyl 
alcohol, isopropyl myristate, stearic acid, beeswax, sperma-
ceti, Tween 20, Tween 80, Span 60, and sorbitan monooleate 
were purchased from Merck (Germany). CoQ10 was from 
Sigma-Aldrich (St. Louis, MO, USA), and all other chemicals 
were analytical reagent grade.
Methods
Preparation of solid lipid nanoparticles
The lipid phase was melted and the drug was dispersed in the 
lipid melt to obtain a clear solution. The dispersion medium 
(ie, distilled water with surfactants) was heated to the temper-
ature of the lipid melt. The hot lipid phase was dispersed in a 
surfactant solution by high-speed stirring using   Ultra-Turrax 
T25 (IKA-Werke, Staufen, Germany). The dispersion was 
then subjected to high-pressure homogenization using IKA 
HPH (2000/4 SH5, Germany). The obtained nanodispersion 
was allowed to cool down to room temperature, forming 
lipid nanoparticles by recrystalization of the dispersed lipid.9 
Different lipids, including beeswax, spermaceti, Comperitol 
888, cetyl alcohol, stearyl alcohol, stearic acid, and cetyl 
palmitate, were tested. We used Tween 80, Tween 20, and 
Tego Care 450 as our surfactants.
Preparation of oil/water cream
Both the lipid and aqueous phases of the cosmetic cream were 
heated separately to 75°C. Hot water was then added to the 
lipid phase with stirring. The resulting emulsion cooled down 
to 40°C and the drug (CoQ10) was added. Under constant 
stirring, the o/w cream cooled down to ambient temperature.9 
For the SLN-containing cream, 50% of the SLN dispersion 
containing Q10 (with a double concentration of Q10) was 
mixed with half of the o/w cream.
Particle size analysis and zeta potential 
measurement
The particle size of SLN dispersions was analyzed using 
photon correlation spectroscopy (PCS) based on the manu-
facturer’s instructions (Zetasizer 4, Malvern Instruments, 
Herrenberg, Germany).
Thermal analysis of sLN dispersions
Differential scanning calorimetry (DSC) studies were per-
formed using a Mettler DSC 821e.The DSC measurements 
were carried out on the following samples: unloaded SLN, 
CoQ10, Q10-loaded SLN (both as lyophilized powder 
forms), and stearic acid as a lipid phase in SLN formulation. 
Each sample (1–3 mg) was transferred into a 40 µL aluminum 
container, and an empty standard aluminum pan was used 
as reference. The samples were heated from 25°C to 85°C 
and subsequently cooled down to 0°C at a rate of 5°C/min 
while flushing with nitrogen (80 mL/min). Each experiment 
was carried out in triplicate.
Transmission electron microscopy
Transmission electron microscopy (TEM) was performed 
at the Faculty of Science using HU-12A (Hitachi Ltd, Mito, 
Japan). One drop of nanoparticle dispersion (aqueous solution 
of SLN) was placed on the copper grid and then negatively 
stained with one drop of 2% (weight/volume) aqueous solu-
tion of phosphotungstrate acid for contrast enhancement. 
The samples were allowed to dry before examination under 
the TEM.International Journal of Nanomedicine 2011:6
Table 1 The best formulation of solid lipid nanoparticles when 
the percentage of solid lipid changes
Ingredient Weight/weight 
percentage
The best 
formulation
Oil phase solid lipid 10–30 13
coenzyme Q10 0.01 0.01
Water phase hydrophilic surfactant 13 13
Distilled water 57–77 74
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In vitro release study
An automated, temperature-controlled continuous flow 
through diffusion cells (six cells) was used to evaluate the 
amount of drug released from the developed formulations. 
The diffusion cells (surface area 0.64 cm²) were thermoregu-
lated with a water jacket at 37°C. Cellulose nitrate membrane 
filters were soaked with water and mounted to diffusion cells. 
Aqueous solution of 5% labrasol was used as a receptor fluid 
and passed through the receptor chamber at a controlled 
rate using a multichannel peristaltic pump. One milliliter of 
samples (Q10-loaded SLN cream, Q10 simple cream, Q10-
loaded SLN) was applied to the donor compartment. Samples 
were collected over 7 hours and analyzed by HPLC according 
to the method of Teeranachaideekul et al.17
In vivo skin hydration and viscoelasticity 
studies
corneometer measurement
Skin hydration was investigated using a corneometer, which 
was mounted on a multiprobe adapter. Capacitance changes 
depending almost solely on the water content in the stratum 
corneum were detected and evaluated. Three measurements 
were performed in each testing area on the forehead. The 
results are given in arbitrary units. Statistical evaluation was 
performed by Student’s t-test.
cutometer measurement
The viscoelastic properties of the skin were investigated with 
a cutometer (Dermalab®, Cortex, Denmark). The measuring 
principle is suction/elongation ratio. Each measurement con-
sisted of three suction cycles (3 seconds of suction followed 
by 3 seconds of relaxation) and was performed in triplicate 
on the forehead. The absolute parameter and the relative 
parameter were evaluated as reference.
skin ph measurement
The skin pH of subjects before and after a 2-month period of 
using the creams was measured by a pH-meter (Dermalab®, 
Cortex, Denmark).
study design
The study was designed as double-blind research. Twenty-
five healthy females (average age 22 ± 2 years) with healthy 
skin who signed informed consent forms used one of the test 
formulations: formulation A (Q10 simple cream) or formu-
lation B (Q10-loaded SLN cream). They were asked not to 
wear any other moisturizer or antiaging products on their 
face 1 week before and during the clinical trial. They had to 
use the cream once every 24 hours at night on their face. The 
skin properties were measured on day 0 (basic value, prior to 
application of the creams) and after 30 and 60 days. On days 
30 and 60, the creams were not applied prior to the measure-
ments. The study was approved by the Ethics Committee of 
Tehran University of Medical Sciences in accordance with the 
Helsinki Declaration and guidelines of the Iranian Ministry 
of Health and Medical Education.
statistics
The data are presented as mean values ± standard deviation. 
  Significance of difference was evaluated using Student’s 
t-test and Kolmogorov–Smirnov test at the probability level 
of 0.05.
Results and discussion
Formulation optimization
CoQ10 is practically insoluble in water and has high solubil-
ity in the lipid, so it was incorporated into the lipid phase of 
the SLN formulation. In order to optimize CoQ10-loaded 
SLN, different formulation variables such as type and con-
centration of surfactants and solid lipids were evaluated and 
the nanoparticle dispersions were characterized for physico-
chemical properties such as color and stability after storing 
at different temperatures (4°C, 25°C, and 40°C).
Table 1 shows formulations with different solid lipids 
ranging between 10% and 30% and a fixed amount of hydro-
philic surfactant. The most stable formulation was selected 
for the next experiment.
Table 2 shows formulations with a fixed amount of solid 
lipid and a variable amount of surfactants. The selected for-
mulation was determined based on the best results in stability, 
size, and appearance.
In the next step, the best formulation shown in Table 2 was 
made with different lipids, including beeswax,   spermaceti, 
Comperitol 888, cetyl alcohol, stearyl alcohol, stearic 
acid, and cetyl palmitate. We used Tween 80, Tween 20, 
and Tego Care 450 as our surfactants. The percentages of 
  ingredients were not changed.International Journal of Nanomedicine 2011:6
Table 2 The best formulation of solid lipid nanoparticles when 
the percentage of surfactant changes
Ingredient Weight/weight 
percentage
The best 
formulation
Oil phase solid lipid 13 13
coenzyme Q10 0.01 0.01
Water phase hydrophilic surfactant 8–18 8
Distilled water 69–79 79
Table 3 The best formulations of solid lipid nanoparticles (sLNs) with suitable stability and particle size
No. Solid lipid Surfactant Water 
phase
Active 
ingredient
Particle 
size (nm)
Zeta 
potential (mV)
Polydispersity 
index
sLN1 cetyl palmitate Tegocare 450 Water Q10 100 ± 15 -44.4 0.203
sLN2 stearic Acid Tween 80 Water Q10   50 ± 10 -47.1 0.109
Percentage 
of above ingredients
13 8 79 0.01
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Based on our data shown in Table 3, the formulations con-
taining stearic acid and cetyl palmitate as lipids had the most 
stability, smallest size, and best appearance. The measured zeta 
potentials for both SLNs indicated very good shelf life physi-
cal stability, and polydispersity index values were lower than 
0.2, suggesting a relatively narrow size   distribution.17 Data for 
all of the formulated SLNs were not shown. The hydrophilic–
lipophilic balance value and the structure of surfactant have 
significant effects on formulation quality. Based on the results 
depicted in Table 3, we selected SLN2 as our best formulation, 
then the best formulation was incorporated into the cream 
base. Table 4 shows the ingredients of the cream base.
The characterization of optimized sLNs
stability study
Not all of the SLNs exhibited good stability during storage. 
Some SLNs showed chemical or physical instabilities. The 
physical stability of the SLNs during prolonged storage 
was determined by monitoring changes in zeta potential, 
particle size, drug content, and appearance. Among those 
formulations prepared from different surfactants and lipids, 
the SLNs shown in Table 3 showed suitable physical and 
chemical stability during the 6-month period of the study. 
No obvious color change, degradation, or phase separation 
was observed. The mean diameter of Q10-loaded SLNs and 
the entrapment efficiency were measured at 50–100 nm and 
99% ± 0.5%, respectively.
Particle size analysis
TEM of SLN dispersion of Q10 showed the spherical shape 
nanoparticles entrapping Q10. Figure 1 shows a monolayer 
coating of surfactant surrounding solid lipids. The TEM 
studies confirmed the observed particle size of SLNs ranging 
between 50 nm and 100 nm.
To study the connection between lipid content and the 
achieved particle size, we measured the particle size of 
different formulations with variable amount of stearic acid 
and a fixed amount of Tween 80. As depicted in Figure 2, 
elevation of the lipid content of formulation increased the 
particle size of SLNs.
Due to desired physicochemical specifications, we also 
selected the formula SLN2 for our in vivo study.
Thermal analysis
We used DSC for detecting potential drug-excipient incompat-
ibilities as well as melting and recrystallization behavior of 
crystalline materials like SLNs. As depicted in Figure 3, the 
DSC profiles of stearic acid as a solid lipid component of SLN 
formulation showed apparent endothermic peaks at about 63°C. 
We detected the melting point of CoQ10 at 54°C. The profile of 
the lyophilized powder of Q10-loaded SLN showed a single peak 
around 57°C, whereas the SLN without Q10 had an endothermic 
peak at 58°C. The height of the endotherm in the thermogram 
of SLN-containing Q10 was less than that in SLN without 
Q10, suggesting loss of crystallinity of the lipids and Q10 after 
incorporation into SLN.9 During the production procedure, Q10 
was dissolved in the melted lipid phase. Stearic acid showed one 
peak at 63°C, indicating no polymorphic forms.
The peak of stearic acid in the formulation had a slight 
shift to the lower temperature side. This could be due to a 
reduction in particle size and an increase in surface area, 
leading to a decrease in melting enthalpy.
The results indicate that Q10 incorporated in SLN was not 
in a crystalline state but in an amorphous form. When the mate-
rials were formulated as SLN, the endothermic temperature was 
lower. Along with a certain effect of surfactants, the observed 
depressed endothermic peak for SLN may be due to the 
nanometric size of the particles with a huge surface area.
In vitro release study
As shown in Figures 4 and 5, the release of Q10 from SLN 
and SLN cream was faster than from simple cream. Due to 
the solid matrix of the nanoparticles and the subsequent drug International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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immobilization, the release of encapsulated Q10 appeared 
different from that of Q10 cream. The PCS mean diameter of 
the SLN dispersion was 50 nm, whereas it was about 1 µm 
in the simple emulsion.
The percentage of released Q10 from simple cream was 
more than for SLN and SLN cream at the first hour time point, 
but after 7 hours it released only about 40% of Q10 contents, 
whereas SLN and SLN cream released almost all of the Q10 
contents, which almost reflected what was reported by Teera-
nachaideekul et al.17 The initial release within the first 5 hours 
was faster for the SLN formulation than for the simple cream, 
which can be explained by enrichment of Q10 in the outer shell 
of the particles. The prolonged release in the second phase can 
be explained by slower diffusion of Q10 from the solid lipid of 
SLN. The solid lipid matrix creates a slow release pattern of 
Q10. The Q10 release from the cream formulation appeared 
to be slower than release from SLN and SLN cream, although 
it did not reach a   significant level. It has been reported that 
chemical stability of Q10 increases after incorporation into 
lipid nanoparticles.18–20 The SLN cream has a higher viscosity 
compared with SLN alone, which slows down the release. In 
the simple cream, Q10 appeared to mix homogenously with 
the cream base, leading to an almost constant Q10 release, 
which could be explained by Fick’s law of diffusion.
In vivo study
In order to avoid low viscosity of SLN dispersions, which 
makes them undesirable to apply on the skin, we incorporated 
the lipid dispersion into a cream base (Table 4). Our in vivo 
study was designed as a double-blind investigation and was 
conducted on 25 healthy females as described before.
After 1 month of topical application, both formulations 
showed an increase in skin humidity of 40% and 65% for 
simple cream and SLN cream, respectively. The elasticity 
of skin was also improved 5% and 120% for simple cream and 
SLN cream users, respectively. Surprisingly, after 2 months, in 
simple cream users a 40% increase in skin humidity and 20% 
elasticity enhancement was observed, whereas in SLN cream 
users we detected a 120% and 125% increase in skin humidity 
and elasticity, respectively. The SLN cream profoundly 
increased both skin humidity and elasticity when compared 
with simple cream. The results are shown in Figures 6 and 7.
Improving skin hydration and elasticity may be due to the 
formation of a film on the skin and subsequent occlusive effect 
of the film. The occlusive effect of lipid nanoparticles has 
already been reported.14 The highest occlusion is achievable 
by using low melting lipids and very small particles, which in 
turn reduce water loss. The skin hydration effect is increased 
after dermal application of SLN-containing formulations. 
The o/w cream containing SLN drastically increased the skin 
hydration when it was compared with simple o/w cream.
The skin pH was slightly reduced after both SLN cream 
and simple cream applications, which might be due to the 
acidic nature of the formulation ingredients.
Conclusion
SLNs have been used as carrier for CoQ10 to protect it 
from degradation, releasing it in a controlled fashion and 
increasing the effectiveness of active ingredients. The data 
presented here clearly demonstrate that the formulations of 
SLN-containing stearic acid and cetyl palmitate as lipids 
achieved a high stability, small size, and good appearance. 
The collected zeta potentials for both of the SLNs indicated 
very good physical stability during the shelf life, and poly-
dispersity index values were lower than 0.2, indicating a 
relatively narrow size distribution. No obvious changes of 
Table 4 Ingredients used in formulation of simple cream and 
cream containing solid lipid nanoparticles
Solid lipid nanoparticle Simple cream
Oil phase  stearic acid 13% cetyl alcohol 1%
stearyl alcohol 1%
cetyl palmitate 1%
Isopropyl myristate 10%
Water phase Distilled water 79% Distilled water 82%
Tween 80 8% Tween 80 3.5%
span 60 1.5%
Active ingredient coenzyme Q10 0.02%
Figure 1 Transmission electron microscopy photograph of a Q10-loaded solid lipid 
nanoparticle.
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Solid lipid nanoparticle
Q10-loaded solid lipid 
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Figure 3 Differential scanning calorimetry thermogram of sample A (stearic acid), sample B (coenzyme Q10), sample c (solid lipid nanoparticle), and sample D (Q10-loaded 
solid lipid nanoparticle).
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Figure  6  Percentage  of  increase  in  hydration  for  simple  cream  and  solid  lipid 
nanoparticle (sLN) cream containing Q10 after 1- and 2-month application periods. 
All results are expressed as values related to the measured values on day 0 and the 
untreated control (mean ± standard deviation, n = 25; P , 0.05).
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Figure 7 Percentage of increase in elasticity for simple and solid lipid nanoparticle 
(sLN) cream containing Q10 after 1- and 2-month application periods. All results 
are expressed as values related to the measured values on day 0 and the untreated 
control (mean ± standard deviation, n = 25; P , 0.05).
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Figure  5  Percentage  of  released  Q10  versus  time  for  simple  Q10,  solid  lipid 
nanoparticle (sLN), and Q10-loaded sLN cream.
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Figure 4 concentration of released Q10 versus time for simple Q10, solid lipid 
nanoparticle (sLN), and Q10-loaded sLN cream.International Journal of Nanomedicine
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color, degradation, or phase separation were observed. The 
mean diameter of Q10-loaded SLN was 50–100 nm and the 
entrapment efficiency was about 99% ± 0.5%. The TEM 
studies confirmed this particle size analysis. The results of 
DSC indicated that Q10 incorporated in SLN was not in a 
crystalline state but in an amorphous form. When the mate-
rial was formulated as SLN, the endothermic temperature 
was lower. The depressed endothermic peak for SLN may be 
due to the nanometric size of the particles, which had a huge 
surface area in addition to a certain surfactant effect.
The initial release within the first 5 hours was faster for 
SLN formulation compared with the simple cream, which can 
be explained by enrichment of Q10 in the outer shell of the 
particles. The prolonged release in the second phase can be 
explained by slower diffusion of Q10 from the solid lipid of 
SLN. The solid lipid matrix creates a slow release pattern of 
Q10. Comparing the drug release from SLN and SLN cream, 
the release of Q10 was slower from the cream formulation, 
although it did not reach a significant level.
We also found that SLN cream increased skin humidity 
and elasticity much more than did simple cream. Skin hydra-
tion and elasticity enhancement is a desirable effect in dermal 
preparations, especially in antiwrinkle creams.
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Figure 8 changes in skin ph after using solid lipid nanoparticle (sLN) cream and 
simple cream (mean ± standard deviation, n = 25; P , 0.05).